{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:30:43Z","timestamp":1786987843375,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eclinm.2025.103521","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:36:17Z","timestamp":1758616577000},"page":"103521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-101X","authenticated-orcid":false,"given":"Erich","family":"Tusch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Ryom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1082-8093","authenticated-orcid":false,"given":"Christian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Degen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5375-7299","authenticated-orcid":false,"given":"Robert","family":"Zangerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-6723","authenticated-orcid":false,"given":"Huldrych F.","family":"G\u00fcnthard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-4289","authenticated-orcid":false,"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-7170","authenticated-orcid":false,"given":"J\u00f6rg Janne","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2641-4327","authenticated-orcid":false,"given":"Josip","family":"Begovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Dos Santos Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Tallada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-4462","authenticated-orcid":false,"given":"Justyna","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-1940","authenticated-orcid":false,"given":"Katharina","family":"Kusejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Jaschinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Reekie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9939","key":"10.1016\/j.eclinm.2025.103521_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration","volume":"384","author":"Smith","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103521_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QAD.0000000000001335","article-title":"Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population","volume":"31","author":"Gueler","year":"2017","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103521_bib3","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/cid\/ciae228","article-title":"Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration","volume":"79","author":"Tusch","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103521_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/15284336.2018.1523826","article-title":"Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system","volume":"19","author":"Horberg","year":"2018","journal-title":"HIV Clin Trials"},{"issue":"19","key":"10.1016\/j.eclinm.2025.103521_bib5","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103521_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103521_bib7","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023","volume":"24","author":"Ambrosioni","year":"2023","journal-title":"HIV Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103521_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103521_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103521_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/dkad364","article-title":"Efficacy and safety of raltegravir plus lamivudine maintenance therapy","volume":"79","author":"Borjabad","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103521_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/aid.2020.0078","article-title":"Overall tolerability of integrase inhibitors in clinical practice: results from a multicenter Italian cohort","volume":"37","author":"Ciccullo","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103521_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/QAI.0000000000002250","article-title":"Uptake and discontinuation of integrase inhibitors (INSTIs) in a large cohort setting","volume":"83","author":"Greenberg","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103521_bib14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1473-3099(11)70196-7","article-title":"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial","volume":"11","author":"Eron","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103521_bib15","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/v2071347","article-title":"Resistance to integrase inhibitors","volume":"2","author":"M\u00e9tifiot","year":"2010","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103521_bib16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/QAD.0b013e3283473599","article-title":"Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143","volume":"25","author":"M\u00e9tifiot","year":"2011","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103521_bib17","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2352-3018(22)00046-7","article-title":"Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study","volume":"9","author":"Trickey","year":"2022","journal-title":"Lancet HIV"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103521_bib18","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","article-title":"Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis","volume":"3","author":"Kanters","year":"2016","journal-title":"Lancet HIV"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103521_bib19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/cid\/cix199","article-title":"Incident AIDS or death after initiation of human immunodeficiency virus treatment regimens including raltegravir or efavirenz among adults in the United States","volume":"64","author":"Cole","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103521_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/hiv.12557","article-title":"Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens","volume":"19","author":"Cozzi-Lepri","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.eclinm.2025.103521_bib21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2025.01.013","article-title":"Comparative effectiveness of bictegravir versus dolutegravir, raltegravir, and efavirenz-based antiretroviral therapy among treatment-na\u00efve individuals with HIV","volume":"133","author":"N\u00fa\u00f1ez","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103521_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae446","article-title":"Comparative effectiveness of switching to bictegravir from Dolutegravir-, Efavirenz-, or raltegravir-based antiretroviral therapy among individuals with HIV who are virologically suppressed","volume":"11","author":"N\u00fa\u00f1ez","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103521_bib23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"28","key":"10.1016\/j.eclinm.2025.103521_bib24","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103521_bib25","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/microorganisms8081164","article-title":"How to RESPOND to modern challenges for people living with HIV: a profile for a new cohort consortium","volume":"8","year":"2020","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103521_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAD.0000000000003402","article-title":"Incidence and risk factors for suicide, death due to substance use, and violent\/accidental death in persons living with HIV","volume":"37","author":"Tusch","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.eclinm.2025.103521_bib27","author":"Nelson"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103521_bib28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/sim.4780100317","article-title":"Confidence intervals for weighted sums of Poisson parameters","volume":"10","author":"Dobson","year":"1991","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2025.103521_bib29","author":"Ramsey"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103521_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1214\/ss\/1038425655","article-title":"Flexible smoothing with B-splines and penalties","volume":"11","author":"Eilers","year":"1996","journal-title":"Stat Sci"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103521_bib31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/aje\/kwu181","article-title":"The role of prediction modeling in propensity score estimation: an evaluation of logistic regression, bCART, and the covariate-balancing propensity score","volume":"180","author":"Wyss","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103521_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/rssb.12027","article-title":"Covariate balancing propensity score","volume":"76","author":"Imai","year":"2013","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103521_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26123","article-title":"Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States","volume":"26","author":"Rebeiro","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.eclinm.2025.103521_bib34","author":"Kuhn"},{"key":"10.1016\/j.eclinm.2025.103521_bib35","series-title":"R: A Language and Environment for Statistical Computing","year":"2019"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103521_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hiv.12810","article-title":"The EuroSIDA study: 25 years of scientific achievements","volume":"21","author":"Laut","year":"2020","journal-title":"HIV Med"},{"issue":"RR-17","key":"10.1016\/j.eclinm.2025.103521_bib37","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"issue":"40","key":"10.1016\/j.eclinm.2025.103521_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035407","article-title":"Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir","volume":"102","author":"Pati\u00f1o Escarcina","year":"2023","journal-title":"Medicine (Baltimore)"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:25:41Z","timestamp":1769059541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025004547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"alternative-id":["S2589537025004547"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103521","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103521"}}